First Patient Treated With Investigational ABBV-383 in CERVINO Phase III Study for Multiple Myeloma
Global, multicenter, randomized, open-label, parallel-group study will evaluate ABBV-383 in adult patients with relapsed/refractory multiple myeloma.
AbbVie has announced that the first patient has been treated with its investigational ABBV-383 in the CERVINO Phase III study (NCT06158841). The trial is a global, multicenter, randomized, open-label, parallel-group study evaluating the investigational therapy in adult patients with relapsed/refractory multiple myeloma who received at least two lines of prior therapy.1
According to AbbVie, ABBV-383 is a distinctive B-cell maturation antigen (BCMA) and CD3 bispecific antibody T-cell engager composed of bivalent BCMA-binding domains allowing for high BCMA-avidity and a low-affinity CD3 binding domain.
"Despite notable advances in treatment, most patients with multiple myeloma will eventually relapse. Patients with advanced disease, especially in the community setting, often have limited access to novel treatment options and existing options have a high treatment burden, including frequent dosing," Peter Voorhees, MD, clinical professor of medicine, director of plasma cell disorders, Atrium Health Levine Cancer Institute said in a press release "The CERVINO Phase III trial is designed to evaluate the efficacy of ABBV-383 with monthly dosing and we look forward to seeing the data as it emerges."
The dual primary end points for the study are progression-free survival and overall response rate. Secondary end points include overall survival, complete response (CR) or better, very good partial response or better, rate of minimum residual disease negativity, and change in disease symptoms and physical functioning. Approximately 140 sites are expected to enroll approximately 380 total patients.
In 2024, an estimated 35,780 cases of multiple myeloma will be diagnosed (19,520 in men and 16,260 in women).2
"The start of the CERVINO Phase III trial marks an important step forward in AbbVie's continued commitment to advance new oncology treatments and elevate the standard of care for blood cancer patients," Mariana Cota Stirner, MD, PhD, vice president, therapeutic area head oncology, hematology, AbbVie said in the press release. "ABBV-383 is being evaluated with monthly dosing from the beginning of treatment, with the goal of maximizing treatment simplicity for physicians and patients, if proven in the clinical trials."
References
1. AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383. News release. June 5, 2024. Accessed June 7, 2024. https://www.prnewswire.com/news-releases/abbvie-advances-oncology-pipeline-with-start-of-multiple-myeloma-phase-3-clinical-trial-for-investigational-asset-abbv-383-302164808.html
2. Key Statistics About Multiple Myeloma. American Cancer Society. Updated January 19, 2024. Accessed June 7, 2024. https://www.cancer.org/cancer/types/multiple-myeloma/about/key-statistics.html
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
